Author

N. Zaffaroni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Kentsis· 2 shared A. L. Kung· 2 shared D. Cameron· 2 shared E. De Stanchina· 2 shared F. S. Dela Cruz· 2 shared H. S. Mueller· 2 shared M. Gounder· 2 shared N. Arrighetti· 2 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Kentsis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

Y. Kazansky, H. S. Mueller, D. Cameron, P. Demarest, N. Zaffaroni, N. Arrighetti, V. Zuco, P. S. Mundi, Y. Kuwahara, R. Somwar, R. Qu, A. Califano, E. De Stanchina, F. S. Dela Cruz, A. L. Kung, , A. Kentsis

The paper identifies ATR as a target for combination EZH2 epigenetic therapy in SMARCB1-deficient sarcomas, showing that EZH2 inhibition promotes DNA damage via PGBD5, and that ATR inhibition enhances therapeutic responses.

bioRxiv · May 3, 2024Cancer Biology

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

Y. Kazansky, D. Cameron, H. S. Mueller, P. Demarest, N. Zaffaroni, N. Arrighetti, V. Zuco, Y. Kuwahara, R. Somwar, M. Ladanyi, R. Qu, E. De Stanchina, F. S. Dela Cruz, A. L. Kung, M. Gounder, A. Kentsis

This study identifies mechanisms of resistance to EZH2 inhibition in SMARCB1-deficient cancers and proposes combination therapies to overcome resistance.

bioRxiv · Feb 6, 2023Cancer Biology

SDF-1/CXCR4 inhibition prevents paradoxical generation of cisplatin-induced pro-metastatic niches

G. Bertolini, V. Cancila, M. Milione, G. Lo Russo, O. Fortunato, N. Zaffaroni, M. Tortoreto, G. Centonze, C. Chiodoni, F. Facchinetti, F. Giovinazzo, M. Moro, C. Camisaschi, A. De Toma, C. D'Alterio, , L. Roz

This study shows that cisplatin promotes metastasis by creating pro-metastatic niches, which can be blocked by CXCR4 inhibition.

bioRxiv · Oct 26, 2020Cancer Biology